Vifor Pharma AG
GNHAY
Other OTC38.39
USD
- -
- -
Vifor Pharma AG
GNHAY
(Other OTC)
Recent
price
38.39
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Vifor Pharma AG, a subsidiary of CSL Ltd following its CHF 10.9 billion acquisition completed in August 2022 and now operating as CSL Vifor, develops, manufactures and markets specialty pharmaceuticals focused on iron deficiency, dialysis, nephrology and rare diseases; core products include iron therapies such as Ferinject/Injectafer (ferric carboxymaltose), Maltofer (iron polymaltose) and Venofer (iron sucrose), nephrology treatments like Veltassa (patiromer) for hyperkalemia, Velphoro (sucroferric oxyhydroxide) for hyperphosphatemia, Mircera (methoxy polyethylene glycol-epoetin beta) and Retacrit (epoetin alfa-epbx) as erythropoiesis-stimulating agents, as well as Vifor Fresenius Medical Care Renal Pharma (VFMCRP) offerings including Korsuva/Kapruvia (difelikefalin) for chronic kidney disease-associated pruritus and Rayaldee (calcifediol) for secondary hyperparathyroidism; pipeline assets encompass Tavneos (avacopan) for ANCA-associated vasculitis, Filspari (sparsentan) for IgA nephropathy, Vadadustat, SNF472 and Vamifeport. Founded in 1872 through predecessor entities including Hausmann pharmacy and Vifor Ltd, with headquarters in St. Gallen, Switzerland and operational base in Glattbrugg, the company conducts R&D in Switzerland including sites in Schlieren and Zurich, manufactures active pharmaceutical ingredients for iron therapies in St. Gallen, and operates in over 100 countries across North and South America, Europe, the Middle East and Asia Pacific, with subsidiaries such as Sanifit Therapeutics in Spain and Inositec in Zurich, plus a leading position via Vifor Fresenius Kabi in China's clinical nutrition, anesthesia and nephrology markets. Recent developments include European Commission approval of Filspari (sparsentan) converting to standard marketing authorization for IgA nephropathy in April 2025, a strategic collaboration and option agreement with VarmX announced in September 2025 for a novel investigational coagulation treatment, Ferinject approval in China for iron deficiency, ongoing commercialization of Tavneos and Korsuva following 2021 approvals, integration post-CSL acquisition with staff optimizations in 2023, and prior deals such as the 2020 joint venture with Fresenius Kabi in China and licensing pacts with Cara Therapeutics, Travere Therapeutics and ChemoCentryx.